FindTrial
Sign In

Folic acid 350-1000 μg

DIETARY_SUPPLEMENT4 trials

Sponsors

Merck Sharp & Dohme LLC, Checkpoint Therapeutics, Inc., Shanghai Chest Hospital

Conditions

Metastatic Non-squamous Non Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNon-squamous NSCLC

Phase 2

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients
Active, not recruitingNCT05751187
Shanghai Chest HospitalNon-squamous NSCLC
Start: 2023-06-27End: 2027-12-30Target: 54Updated: 2026-03-11

Phase 3

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
CompletedNCT02578680
Merck Sharp & Dohme LLCNon-Small-Cell Lung Carcinoma
Start: 2016-01-15End: 2023-06-22Updated: 2024-09-20
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
CompletedNCT03950674
Merck Sharp & Dohme LLCNon-Small-Cell Lung Carcinoma
Start: 2016-02-22End: 2023-06-22Updated: 2024-06-10
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
TerminatedNCT04786964
Checkpoint Therapeutics, Inc.Metastatic Non-squamous Non Small Cell Lung Cancer
Start: 2021-12-08End: 2023-12-30Updated: 2025-04-02

Related Papers

Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer.
2025-06-11
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up
Journal of Thoracic Oncology2024-04-1834 citations
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
Nature Communications2023-11-1124 citations
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
Journal of Clinical Oncology2023-02-21530 citations
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
2022-11-0826 citations
581 Matching-adjusted indirect treatment comparison of tremelimumab + durvalumab + chemotherapy vs pembrolizumab + chemotherapy and nivolumab + ipilimumab + chemotherapy for first-line metastatic NSCLC
Regular and Young Investigator Award Abstracts2022-11-01
External control cohorts for the single-arm LIBRETTO-001 trial of selpercatinib in RET+ non-small-cell lung cancer.
2022-08-0210 citations
364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
Regular and Young Investigator Award Abstracts2021-11-01
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
2021-04-22311 citations
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
2021-02-1911 citations
Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer.
2021-01-013 citations
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
Cancer2020-09-11107 citations
Abstract LB-397: Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by <i>STK11</i> and <i>KEAP1</i> status
Cancer Research2020-08-1516 citations
Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2020-05-2025 citations
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
Journal of Clinical Oncology2020-05-2024 citations
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer
Journal of Clinical Oncology2020-03-091122 citations
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
2020-02-06164 citations
Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189.
Journal of Clinical Oncology2020-02-041 citations
Pembrolizumab Plus Chemo for Advanced Non-Small Cell Lung Cancer
Oncology Times2019-11-14
KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.
Journal of Clinical Oncology2019-05-2065 citations

6 more papers not shown